Delivery Order SPE2DB24D2101-SPE2DB25FKNUL
- Not listed
- The Defense Logistics Agency awarded a $41,178.10 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This competitively awarded, firm fixed-price contract is non-set-aside and scheduled for completion by August 21, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an immune globulin intravenous (human) product used in treating immune deficiency disorders and is a critical pharmaceutical...
- The Defense Logistics Agency awarded a $7,080.84 delivery order contract to AmerisourceBergen Drug Corp for GAMUNEX-C (Immune Globulin Intravenous [Human]), a specialized pharmaceutical product supplied in 20 gram/200 milliliter vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine replenishment order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 Gram/400 mL vials, valued at $4,654.40 with a firm fixed price structure. This is an unset-aside, competitively awarded contract with an ultimate completion date of August 20, 2025, and performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat primary...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials, with a contract ceiling value of $2,327.20 and an ultimate completion date of September 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $60,799.14 to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 mL vials on August 22, 2025, with completion scheduled for September 15, 2025. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used to treat primary immunodeficiency and other immune-related conditions. This competitively awarded, firm fixed-price delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $11,636.00 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) therapy used to treat various immunodeficiency and autoimmune conditions, making it a critical...
- The Defense Logistics Agency awarded a $4,555.05 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 5 gram/50 milliliter vials on August 1, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,178.10 on July 24, 2025, for the supply of GAMUNEX-C 40 gram/400 milliliter vials. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order was issued without a set-aside designation, reflecting open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNULDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,831.41 to AmerisourceBergen Drug Corp for GAMUNEX-C 10 Gram/100 ML Vial (100 ML), with an ultimate completion date of September 15, 2025. This firm fixed price contract represents a non-set-aside competitive award and serves as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. GAMUNEX-C is an intravenous immunoglobulin (IVIG) product used for treating primary immunodeficiency disorders and other immune-related conditions. Under its comprehensive IDC vehicle, AmerisourceBergen functions as a global pharmaceutical prime vendor supplying a broad range of medications, vaccines, and medical supplies to support Defense Health Agency and military healthcare programs worldwide. The company's federal contract portfolio reflects its established position as a critical pharmaceutical distributor for the Defense Logistics Agency's Medical Supply Chain, fulfilling delivery orders across multiple therapeutic domains with demonstrated capability in both small-value and large-scale procurement transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/22/25 |